NCT00224718

Brief Summary

Abdominal aortic aneurysm (AAA) is a life threatening disease. There is a consensus to propose surgical repair in patients with a reasonable operative risk when the AAA exceeds 5 cm in diameter. The aim of the study is to compare the mortality and the occurrence of severe general, vascular and local complications in two groups of patients treated by either by open surgery or by EVAR (EndoVascular Aneurysm Repair). The main outcome criteria and the secondary endpoint are respectively the survival without severe complications and minor morbidity.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
306

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jan 2003

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2003

Completed
2.7 years until next milestone

First Submitted

Initial submission to the registry

September 16, 2005

Completed
7 days until next milestone

First Posted

Study publicly available on registry

September 23, 2005

Completed
2.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2008

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2009

Completed
Last Updated

April 1, 2009

Status Verified

February 1, 2009

Enrollment Period

5.1 years

First QC Date

September 16, 2005

Last Update Submit

March 31, 2009

Conditions

Keywords

Abdominal aortic aneurysmEndograftOpen repairEndovascular repairAAA

Outcome Measures

Primary Outcomes (1)

  • Death and major adverse events

    4 years

Secondary Outcomes (1)

  • Minor adverse events (systemic vascular or non vascular complications)

    4 years

Study Arms (2)

1

ACTIVE COMPARATOR

surgery - open repair

Procedure: Open repair

2

EXPERIMENTAL

endovascular procedure

Procedure: Endovascular repair (with endograft)

Interventions

An endovascular stent graft is a tube composed of fabric supported by a metal mesh called a stent. It can be used for a variety of conditions involving the blood vessels, but most commonly to reinforce a weak spot in an artery called an aneurysm. Over time, blood pressure and other factors can cause this weak area to bulge like a balloon and eventually enlarge and rupture. The stent graft seals tightly with your artery above and below the aneurysm. The graft is stronger than the weakened artery and allows blood to pass through it without pushing on the bulge. Physicians typically use endovascular stent grafting to treat abdominal aortic aneurysms (AAAs).

2
Open repairPROCEDURE

Conventional repair consist in open repair. Different types of surgery can be done : minimal incision aortic surgery (MIAS), transperitoneal approach (TPA), retroperitoneal repair, or conventional median laparotomy.

1

Eligibility Criteria

Age50 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients aged 50 years old or more (more than 80 possible depending on physiological age)
  • Level 0, 1, or 2 of operative risk
  • Abdominal aortic aneurysm with a diameter \> or equal to 50 mm or \> or equal to 40 mm if rapid growing (10 mm or more in a year), or painful, or saccular aneurysms, or aneurisms of common iliac arteries with a diameter equal or superior to 30 mm; or women with a diameter equal to 45 mm;
  • Aortic neck superior or equal to 1.5 cm
  • No stenosis superior or equal to 75% of the superior mesenteric artery
  • Proximal neck angulation inferior to 80°
  • Diameter of the iliac arteries compatible with introducer sheath
  • Inform consent signed

You may not qualify if:

  • Aneurysm involving the renal arteries or with the length of the neck less than 1.5 cm
  • Thrombus or major calcification in the neck
  • Diameter of the iliac arteries not compatible with introducer sheath
  • Level 3 of operative risk
  • History of major iodine allergy (Quincke oedema, anaphylactic shock)
  • Other comorbidity with life expectancy less than 6 months
  • Follow up impossible during the trial
  • Participation in another trial
  • Inform consent not signed

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hopital Henri Mondor

Créteil, 94 010, France

Location

Related Publications (2)

  • Lederle FA. Endovascular repair of abdominal aortic aneurysm--round two. N Engl J Med. 2005 Jun 9;352(23):2443-5. doi: 10.1056/NEJMe058126. No abstract available.

    PMID: 15944430BACKGROUND
  • Becquemin JP, Pillet JC, Lescalie F, Sapoval M, Goueffic Y, Lermusiaux P, Steinmetz E, Marzelle J; ACE trialists. A randomized controlled trial of endovascular aneurysm repair versus open surgery for abdominal aortic aneurysms in low- to moderate-risk patients. J Vasc Surg. 2011 May;53(5):1167-1173.e1. doi: 10.1016/j.jvs.2010.10.124. Epub 2011 Jan 26.

Related Links

MeSH Terms

Conditions

Aortic Aneurysm, Abdominal

Condition Hierarchy (Ancestors)

Aortic AneurysmAneurysmVascular DiseasesCardiovascular DiseasesAortic Diseases

Study Officials

  • Yann JOUSSET, MD

    CHU Angers - Hôtel Dieu

    PRINCIPAL INVESTIGATOR
  • Jean M Pernes, MD

    Hôpital privé d'Antony

    PRINCIPAL INVESTIGATOR
  • Pierre Y Meaulle, MD

    Clinique mutualiste des Eaux Claires, Grenoble

    PRINCIPAL INVESTIGATOR
  • Jean P Favre, MD

    CHU Hôpital Nord, Saint-Etienne

    PRINCIPAL INVESTIGATOR
  • Jacques Watelet, MD

    Hôpital Charles Nicolle, Rouen

    PRINCIPAL INVESTIGATOR
  • Patrick Lermusiaux, MD

    CHRU -Hôpital Trousseau, Tours

    PRINCIPAL INVESTIGATOR
  • Jean F Heautot, MD

    CHU de Pontchaillou, Rennes

    PRINCIPAL INVESTIGATOR
  • Mohamad KOUSSA, MD

    Hôpital Cardiologique , Lille

    PRINCIPAL INVESTIGATOR
  • Patrice BERGERON, MD

    Hôpital St Joseph, Marseille

    PRINCIPAL INVESTIGATOR
  • Philippe CHAILLOU, MD

    Hôpital Nord Laennec, Nantes

    PRINCIPAL INVESTIGATOR
  • Eric CHEYSSON, MD

    Centre Hospitalier René Dubos, Pontoise

    PRINCIPAL INVESTIGATOR
  • Arnaud DEMON, MD

    CH de Valenciennes

    PRINCIPAL INVESTIGATOR
  • Jean C PILLET, MD

    Nouvelles Cliniques Nantaises, Nantes

    PRINCIPAL INVESTIGATOR
  • Eric STEINMETZ, MD

    CHU de Dijon - Hôpital du Bocage

    PRINCIPAL INVESTIGATOR
  • Michel LEVADE, MD

    Clinique Pasteur Toulouse

    PRINCIPAL INVESTIGATOR
  • Jean CARDON, MD

    Clinique des Franciscaines, Nimes

    PRINCIPAL INVESTIGATOR
  • Pierre-Edouard MAGNAN, MD

    CHU Timone, Marseille

    PRINCIPAL INVESTIGATOR
  • Michel Batt, MD

    Hôpital St-Roch, Nice

    PRINCIPAL INVESTIGATOR
  • Pierre GOUNY, MD

    Hopital de la cavale blanche, Brest

    PRINCIPAL INVESTIGATOR
  • Antoine Lucas, MD

    CHU Pontchaillou

    PRINCIPAL INVESTIGATOR
  • Jean P Becquemin, MD

    Hopital Henri Mondor, Créteil

    STUDY CHAIR
  • Marc Sapoval, MD

    HEGP, Paris

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

September 16, 2005

First Posted

September 23, 2005

Study Start

January 1, 2003

Primary Completion

February 1, 2008

Study Completion

February 1, 2009

Last Updated

April 1, 2009

Record last verified: 2009-02

Locations